Results 101 to 110 of about 85,257 (242)
The impact of systemic long‐term medications for the development of age‐related macular degeneration
Acta Ophthalmologica, EarlyView.Abstract Purpose Age‐related macular degeneration (AMD) is a leading cause of central vision loss in the elderly; however, the systemic factors that modulate its incidence and progression remain unclear. We sought to determine whether long‐term use of systemic medications, including diabetes and antithrombotic medications, corticosteroids and ...
Hanna Heloterä +3 more
wiley +1 more source
Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits
Clinical Ophthalmology, 2011 Christos I Sinapis1,*, John G Routsias2,*, Angelos I Sinapis1,*, Dimitrios I Sinapis1,*, George D Agrogiannis3, Alkistis Pantopoulou1, Stamatis E Theocharis4, Stefanos Baltatzis5, Efstratios Patsouris3, Despoina Perrea11Laboratory for Experimental ...
Sinapis C +9 more
doaj
World Journal of Surgical OncologyObjective The clinical benefits of neoadjuvant bevacizumab plus chemotherapy in locally advanced gastric cancer patients are controversial. This study intended to evaluate the efficacy and safety of neoadjuvant bevacizumab plus chemotherapy in these ...
Bin Yin, Wei Luo
doaj +1 more source
Acta Ophthalmologica, EarlyView.Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car +3 more
wiley +1 more source
Acta Ophthalmologica, EarlyView.Abstract Coats disease diagnosed in adulthood is a rare idiopathic retinal telangiectatic vasculopathy that may differ in phenotype from childhood‐diagnosed cases. This systematic review synthesizes current evidence to characterize its clinical spectrum, imaging features, treatment outcomes and underlying mechanisms, with a focus on immunovascular ...
Catarina Francisco +2 more
wiley +1 more source
Acta Ophthalmologica, EarlyView.Abstract Purpose To evaluate real‐world safety experience with aflibercept 8 mg in a large case series of patients with neovascular age‐related macular degeneration (nAMD). Methods Due to a high proportion of patients on short treatment intervals, patients with nAMD at a Danish tertiary retina clinic were systematically switched to aflibercept 8 mg ...
Mary Graciya Karunainathan +12 more
wiley +1 more source
Impact of delayed appointments on treatment outcomes in neovascular macular degeneration
Acta Ophthalmologica, EarlyView.Abstract Purpose To evaluate the real‐world visual outcomes of anti‐vascular endothelial growth factor (anti‐VEGF) therapy, the frequency of delayed appointments and the relationship between delays and visual outcomes in patients with neovascular age‐related macular degeneration (nAMD).
Petri Purola +3 more
wiley +1 more source
Five Advances in the Last 50 Years: Liver Malignancies
World Journal of Surgery, EarlyView.
Alex B. Blair, Timothy M. Pawlik
wiley +1 more source
Three years of ocular proton therapy in the Netherlands, clinical results
Acta Ophthalmologica, EarlyView.Abstract Purpose Uveal melanoma (UM) is a rare cancer with rising number of diagnosis (143 diagnoses in 1990 to 226 in 2023) in the Netherlands. Most patients are treated locally with Ruthenium‐106 brachytherapy (±102/year). Patients were referred for proton therapy (PT) to Switzerland in the past, but PT is available in the Netherlands from January ...
C. Rasch +14 more
wiley +1 more source